SCHEDULE: Contrarian Funds & Parker Quillen Disclose 4.9% Stake in Achieve Life Sciences
Beneficial Ownership Report
Contrarian Alpha, Contrarian Achieve SPV, and related entities, along with Parker Quillen, report beneficial ownership of 4.9% of Achieve Life Sciences, Inc. common stock.
Summary
- Contrarian Alpha, LP, Contrarian Achieve SPV, LP, and related entities, including Parker Quillen, collectively report beneficial ownership in Achieve Life Sciences, Inc.
- Parker Quillen, as the manager of the general partners, is deemed to beneficially own an aggregate of 2,528,377 shares of Common Stock.
- This aggregate ownership represents approximately 4.9% of the outstanding Common Stock of Achieve Life Sciences, Inc., based on 51,104,968 shares outstanding as of August 7, 2025.
- The ownership includes both directly held shares and warrants currently exercisable for additional shares.
- Specifically, Contrarian Achieve SPV, LP beneficially owns 1,978,377 shares (3.8%), comprising 1,318,918 direct shares and warrants for 659,459 shares.
- Contrarian Alpha, LP beneficially owns 550,000 shares (1.1%), comprising 350,000 direct shares and warrants for 200,000 shares.
- The reporting persons certify that the securities were not acquired for the purpose of changing or influencing control of the issuer, except for activities related to nominations under Rule 14a-11.
Sentiment
Score: 5
Explanation: This is a neutral disclosure filing regarding beneficial ownership, not containing information that would inherently sway sentiment positively or negatively regarding the issuer's performance or prospects.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding significant beneficial ownership by institutional investors and an individual, which can influence market perception of the stock's liquidity and control.
Key Dates
| Date | Description |
|---|---|
| 2022-11-28 | Date of previous Schedule 13G filing by Reporting Persons with respect to the Issuer. |
| 2025-08-07 | Date of Issuer's Current Report on Form 10-Q, disclosing 51,104,968 shares of Common Stock outstanding. |
| 2025-09-30 | Date of event which requires filing of this statement. |
| 2025-11-07 | Signature date for Parker Quillen. |
| 2025-11-14 | Signature date for Contrarian Alpha, Contrarian Achieve SPV, Contrarian Achieve GP LLC, Contrarian Alpha GP, LLC, and Contrarian Alpha Management, LLC. |
Keywords
Achieve Life Sciences, Common Stock, Contrarian Alpha, Contrarian Achieve SPV, Parker Quillen, Beneficial Ownership, SEC Filing, Schedule 13G, Investment, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.